Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Hovione, Evonik Boost China Pharma Chemicals

March 10, 2008 | A version of this story appeared in Volume 86, Issue 10

Two European pharmaceutical chemical producers are increasing their presence in China. The Portuguese firm Hovione has purchased 75% of China's Hisyn Pharmaceutical, a Shanghai-based producer of active pharmaceutical ingredients. "Hisyn represents an opportunity to both increase our manufacturing capacity and ensure a sustainable cost advantage," says Hovione Chief Financial Officer Miguel Calado. Hovione says Hisyn's four-year-old plant will start producing its two largest volume products. Separately, Evonik Industries has bought out the 49% share of its Degussa Lynchem pharmaceutical chemicals joint venture held by Chinese shareholders. The venture was established in 2006 when Evonik forerunner Degussa bought a 51% stake in Lynchem, based in Dalian, China. "In taking over the remaining shares, we are strengthening our global exclusive synthesis business and further expanding it in line with our successful concept of horizontal integration," says Alfred Oberholz, the Evonik board member responsible for chemicals.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.